Shares of Recursion Pharmaceuticals surged +6.3% to $5.08 on October 6, extending a blistering weekly run from $4.03 to over five dollars — a roughly 26% gain in five trading days — as investors continue to digest the company's reworked partnership with Tempus AI, announced September 21. No new company catalyst was identified today; the move looks like momentum carrying forward on a supportive Nasdaq session (+0.57%).

  • The Deal Cuts Recursion's Bills in Half — But So Does Its Data Access. The amended agreement replaced discretionary license fees that could have totaled $84 million over two years with committed payments of just $42 million over three years. That effectively halves near-term cash outflows to Tempus, a meaningful reprieve for a company that saw Q2 2026 revenue fall 60% to $7.67 million and posted a net loss of $131 million in the quarter. However, the amendment also reduces the total de-identified records Recursion can access — raising a question about whether cheaper means less useful.

  • Licensing Its RNA Model Brings In Cash, Not Just Spend. Recursion entered a two-year license granting Tempus non-exclusive use of its RNA sequencing model in oncology, earning $12 million in two installments plus additional pathology data. For a company whose trailing twelve-month revenue is roughly $55 million , $12 million in guaranteed payments is noticeable. More importantly, it is the first time Recursion has sold access to one of its core AI tools, signaling a possible new revenue stream beyond its traditional pharma collaboration milestones.

  • Cash Runway Matters More Than Revenue Right Now. Management cut FY26 cash operating expense guidance by $15 million to about $375 million — roughly 40% below 2024 levels — and projects a cash runway into early 2028.

Cash stood at $556.8 million as of June 30, 2026. The Tempus restructuring reduces outflows further, but at a burn rate exceeding $100 million per quarter, the cushion is finite.

  • A Heavy Short Position Adds Fuel — and Risk. About 184 million shares — roughly 34.7% of total shares outstanding — have been sold short. That compressed spring can amplify rallies when sentiment turns, which partly explains the outsized move. But a stock that has swung between $2.77 and $7.18 over the past year remains a high-volatility name where momentum can reverse just as sharply.